A Democratic TV ad attacks Sen. Susan Collins for voting twice “to allow drug companies to keep cheaper generic drugs off the market,” but omits the fact that Collins has supported bills intended to increase generic-drug competition and lower prescription costs.
Health and Human Services Secretary Alex Azar has described a new policy as “unleashing our Medicare Advantage plans to negotiate discounting on $12 billion of drugs.” Some patient advocacy groups have described the policy as one that “could erect barriers to care for cancer” and put “insurers in control of treatment decisions.” We’ll explain what the new policy entails.
Gauging by the attack ads flowing from the Democratic Congressional Campaign Committee, the party’s House contenders are running against Exxon, Pfizer and Bush. The ads tie Republican House candidates to unpopular industries and an unpopular President. Some of these ads are exaggerations.
GOP candidate Michael Steele misleadingly accuses Democratic Rep. Ben Cardin of taking “money from special interests” and then voting against importing cheaper prescription drugs from Canada.
The industry wages an $80-million campaign against a California ballot measure to require discounts on prescriptions for middle-income patients.